Molecular Modeling Studies of N-phenylpyrimidine-4-amine Derivatives for Inhibiting FMS-like Tyrosine Kinase-3
Abstract
:1. Introduction
2. Results and Discussion
2.1. Molecular Docking Analysis
2.2. MD Analysis
2.3. MM-PB(GB)SA and LIE Estimation
2.4. Dataset Building, 3D-QSAR Model Development, and Model Validation
2.5. CoMFA and CoMSIA Contour Map Analysis
2.6. Designing of New Compounds
3. Materials and Methods
3.1. Protein Structure Preparation and Molecular Docking
3.2. Molecular Dynamics
3.3. MM-PB(GB)SA and LIE
3.4. Dataset Building, Molecular Alignment, and CoMFA-CoMSIA (3D-QSAR) Study
3.5. Contour Maps Analysis
3.6. Designing of the New Compounds
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
FLT3 | FMS-like tyrosine kinase-3 |
AML | acute myeloid leukemia |
MM-PB(GB)SA | Molecular Mechanics Poison–Boltzmann/Generalized Born Surface Area |
LIE | linear interaction energy |
BE | binding Energy |
CoMFA | comparative molecular field analysis |
CoMSIA | comparative molecular similarity indices analysis |
3D-QSAR | three-dimensional structure–activity relationship |
References
- Wang, Z.; Cai, J.; Cheng, J.; Yang, W.; Zhu, Y.; Li, H.; Lu, T.; Chen, Y.; Lu, S. FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. J. Med. Chem. 2021, 64, 2878–2900. [Google Scholar] [CrossRef]
- Cueto, F.; Sancho, D. The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy. Cancers 2021, 13, 1525. [Google Scholar] [CrossRef] [PubMed]
- Pannecoucke, E.; Raes, L.; Savvides, S.N. Engineering and crystal structure of a monomeric FLT3 ligand variant. Acta Crystallogr. Sect. F Struct. Biol. Commun. 2021, 77, 121–127. [Google Scholar] [CrossRef] [PubMed]
- Yen, S.-C.; Chen, L.-C.; Huang, H.-L.; Ngo, S.-T.; Wu, Y.-W.; Lin, T.E.; Sung, T.-Y.; Lien, S.-T.; Tseng, H.-J.; Pan, S.-L.; et al. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia. J. Nat. Prod. 2021, 84, 1–10. [Google Scholar] [CrossRef]
- Wilson, K.R.; Villadangos, J.A.; Mintern, J.D. Dendritic cell Flt3—regulation, roles and repercussions for immunotherapy. Immunol. Cell Biol. 2021, 99, 962–971. [Google Scholar] [CrossRef]
- Almatani, M.F.; Ali, A.; Onyemaechi, S.; Zhao, Y.; Gutierrez, L.; Vaikari, V.P.; Alachkar, H. Strategies targeting FLT3 beyond the kinase inhibitors. Pharmacol. Ther. 2021, 225, 107844. [Google Scholar] [CrossRef] [PubMed]
- Hasegawa, H.; Taniguchi, H.; Nakamura, Y.; Kato, T.; Fujii, S.; Ebi, H.; Shiozawa, M.; Yuki, S.; Masuishi, T.; Kato, K.; et al. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Sci. 2021, 112, 314. [Google Scholar] [CrossRef]
- Kawase, T.; Nakazawa, T.; Eguchi, T.; Tsuzuki, H.; Ueno, Y.; Amano, Y.; Mori, M.; Yoshida, T. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. Oncotarget 2019, 10, 6111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roskoski, R., Jr. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. Pharmacol. Res. 2020, 155, 104725. [Google Scholar] [CrossRef]
- Bjelosevic, S.; Gruber, E.; Newbold, A.; Shembrey, C.; Devlin, J.R.; Hogg, S.J.; Kats, L.; Todorovski, I.; Fan, Z.; Abrehart, T.C.; et al. Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia. Cancer Discov. 2021, 11, 1582–1599. [Google Scholar] [CrossRef]
- Qiao, X.; Ma, J.; Knight, T.; Su, Y.; Edwards, H.; Polin, L.; Li, J.; Kushner, J.; Dzinic, S.H.; White, K.; et al. The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer J. 2021, 11, 1–17. [Google Scholar] [CrossRef]
- Scholl, S.; Fleischmann, M.; Schnetzke, U.; Heidel, F.H. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. Cells 2020, 9, 2493. [Google Scholar] [CrossRef]
- Mosquera Orgueira, A.; Bao Pérez, L.; Mosquera Torre, A.; Peleteiro Raíndo, A.; Cid López, M.; Díaz Arias, J.Á.; Ferreiro Ferro, R.; Antelo Rodríguez, B.; González Pérez, M.S.; Albors Ferreiro, M.; et al. FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: Current status and future perspectives. Minerva Med. 2020, 111, 427–442. [Google Scholar] [CrossRef]
- Bertoli, S.; Dumas, P.-Y.; Bérard, E.; Largeaud, L.; Bidet, A.; Delabesse, E.; Tavitian, S.; Gadaud, N.; Leguay, T.; Leroy, H.; et al. Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study. Cancers 2020, 12, 773. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bhujbal, S.P.; Keretsu, S.; Cho, S.J. Design of New Therapeutic Agents Targeting FLT3 Receptor Tyrosine Kinase Using Molecular Docking and 3D-QSAR Approach. Lett. Drug Des. Discov. 2020, 17, 585–596. [Google Scholar] [CrossRef]
- Bensinger, D.; Stubba, D.; Cremer, A.; Kohl, V.; Waßmer, T.; Stuckert, J.; Engemann, V.; Stegmaier, K.; Schmitz, K.; Schmidt, B. Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations. J. Med. Chem. 2019, 62, 2428–2446. [Google Scholar] [CrossRef]
- Smith, C.C.; Lin, K.; Stecula, A.; Sali, A.; Shah, N.P. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 2015, 29, 2390–2392. [Google Scholar] [CrossRef] [Green Version]
- Bharate, J.B.; McConnell, N.; Naresh, G.; Zhang, L.; Lakkaniga, N.R.; Ding, L.; Shah, N.P.; Frett, B.; Li, H.-Y. Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. Sci. Rep. 2018, 8, 3722. [Google Scholar] [CrossRef] [PubMed]
- Yamaura, T.; Nakatani, T.; Uda, K.; Ogura, H.; Shin, W.; Kurokawa, N.; Saito, K.; Fujikawa, N.; Date, T.; Takasaki, M.; et al. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood 2018, 131, 426–438. [Google Scholar] [CrossRef] [Green Version]
- Wu, T.-S.; Lin, W.-H.; Tsai, H.-J.; Hsueh, C.-C.; Hsu, T.; Wang, P.-C.; Lin, H.-Y.; Peng, Y.-H.; Lu, C.-T.; Lee, L.-C.; et al. Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants. J. Med. Chem. 2019, 62, 3940–3957. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zorn, J.A.; Wang, Q.; Fujimura, E.; Barros, T.; Kuriyan, J. Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220). PLoS ONE 2015, 10, e0121177. [Google Scholar] [CrossRef] [Green Version]
- Gutiérrez, C.M.; Cáceres-Rojas, D.; Adasme-Carreño, F.; Palomo, I.; Fuentes, E.; Caballero, J. Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors. PLoS ONE 2017, 12, e0189213. [Google Scholar] [CrossRef] [Green Version]
- Caballero, J.; Morales-Bayuelo, A.; Navarro-Retamal, C. Mycobacterium tuberculosis serine/threonine protein kinases: Structural information for the design of their specific ATP-competitive inhibitors. J. Comput. Mol. Des. 2018, 32, 1315–1336. [Google Scholar] [CrossRef]
- Nakaoku, T.; Kohno, T.; Araki, M.; Niho, S.; Chauhan, R.; Knowles, P.P.; Tsuchihara, K.; Matsumoto, S.; Shimada, Y.; Mimaki, S.; et al. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat. Commun. 2018, 9, 1–9. [Google Scholar] [CrossRef]
- Mondal, J.; Tiwary, P.; Berne, B.J. How a Kinase Inhibitor Withstands Gatekeeper Residue Mutations. J. Am. Chem. Soc. 2016, 138, 4608–4615. [Google Scholar] [CrossRef]
- Ahuja, L.G.; Aoto, P.; Kornev, A.P.; Veglia, G.; Taylor, S.S. Dynamic allostery-based molecular workings of kinase:peptide complexes. Proc. Natl. Acad. Sci. USA 2019, 116, 15052–15061. [Google Scholar] [CrossRef] [Green Version]
- Barouch-Bentov, R.; Sauer, K. Mechanisms of drug resistance in kinases. Expert Opin. Investig. Drugs 2011, 20, 153–208. [Google Scholar] [CrossRef]
- Zhang, L.; Tsai, K.-C.; Du, L.; Fang, H.; Li, M.; Xu, W. How to generate reliable and predictive CoMFA models. Curr. Med. Chem. 2011, 18, 923–930. [Google Scholar] [CrossRef]
- Veerasamy, R.; Rajak, H.; Jain, A.; Sivadasan, S.; Varghese, C.P.; Agrawal, R.K. Validation of QSAR models-strategies and importance. Int. J. Drug Des. Discov. 2011, 3, 511–519. [Google Scholar]
- Roy, K.; Chakraborty, P.; Mitra, I.; Ojha, P.K.; Kar, S.; Das, R.N. Some case studies on application of “rm2” metrics for judging quality of quantitative structure-activity relationship predictions: Emphasis on scaling of response data. J. Comput. Chem. 2013, 34, 1071–1082. [Google Scholar] [CrossRef]
- Gramatica, P.; Sangion, A. A Historical Excursus on the Statistical Validation Parameters for QSAR Models: A Clarification Concerning Metrics and Terminology. J. Chem. Inf. Model. 2016, 56, 1127–1131. [Google Scholar] [CrossRef]
- Todeschini, R.; Ballabio, D.; Grisoni, F. Beware of Unreliable Q2! A Comparative Study of Regression Metrics for Predictivity Assessment of QSAR Models. J. Chem. Inf. Model. 2016, 56, 1905–1913. [Google Scholar] [CrossRef] [PubMed]
- Abdizadeh, R.; Hadizadeh, F.; Abdizadeh, T. QSAR analysis of coumarin-based benzamides as histone deacetylase inhibitors using CoMFA, CoMSIA and HQSAR methods. J. Mol. Struct. 2020, 1199, 126961. [Google Scholar] [CrossRef]
- Sahigara, F.; Ballabio, D.; Todeschini, R.; Consonni, V. Assessing the validity of QSARs for ready biodegradability of chemicals: An applicability domain perspective. Curr. Comput. Drug Des. 2014, 10, 137–147. [Google Scholar] [CrossRef]
- Ghosh, S.; Keretsu, S.; Cho, S.J. 3D-QSAR, Docking and Molecular Dynamics Simulation Study of C-Glycosylflavones as GSK-3β Inhibitors. J. Chosun Natural Sci. 2020, 13, 170–180. [Google Scholar]
- Ghosh, S.; Keretsu, S.; Cho, S.J. Computational Modeling of Novel Phosphoinositol-3-kinase γ Inhibitors Using Molecular Docking, Molecular Dynamics, and 3D-QSAR. Bull. Korean Chem. Soc. 2021, 42, 1093–1111. [Google Scholar] [CrossRef]
- Ghosh, S.; Keretsu, S.; Cho, S.J. Designing of the N-ethyl-4-(pyridin-4-yl)benzamide based potent ROCK1 inhibitors using docking, molecular dynamics, and 3D-QSAR. PeerJ 2021, 9, e11951. [Google Scholar] [CrossRef]
- Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A.E.; Berendsen, H.J.C. GROMACS: Fast, flexible, and free. J. Comput. Chem. 2005, 26, 1701–1718. [Google Scholar] [CrossRef]
- Maier, J.A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J. Chem. Theory Comput. 2015, 11, 3696–3713. [Google Scholar] [CrossRef] [Green Version]
- Da Silva, A.W.S.; Vranken, W.F. ACPYPE-Antechamber python parser interface. BMC Res. Notes 2012, 5, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Keretsu, S.; Ghosh, S.; Cho, S. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Int. J. Mol. Sci. 2020, 21, 8232. [Google Scholar] [CrossRef] [PubMed]
- Tresanco, M.S.V.; Valdes-Tresanco, M.E.; Valiente, P.A.; Frías, E.M. gmx_MMPBSA (Version v1.4.3); Zenodo, 2021. [Google Scholar] [CrossRef]
- Miller, B.R., III; McGee, T.D., Jr.; Swails, J.M.; Homeyer, N.; Gohlke, H.; Roitberg, A.E. MMPBSA. py: An efficient program for end-state free energy calculations. J. Chem. Theory Comput. 2012, 8, 3314–3321. [Google Scholar] [CrossRef] [PubMed]
- Rifai, E.A.; van Dijk, M.; Geerke, D.P. Recent Developments in Linear Interaction Energy Based Binding Free Energy Calculations. Front. Mol. Biosci. 2020, 7, 7. [Google Scholar] [CrossRef]
- Ngo, S.T.; Hung, H.M.; Nguyen, M.T. Fast and accurate determination of the relative binding affinities of small compounds to HIV-1 protease using non-equilibrium work. J. Comput. Chem. 2016, 37, 2734–2742. [Google Scholar] [CrossRef]
- Rifai, E.A.; Van Dijk, M.; Vermeulen, N.P.E.; Yanuar, A.; Geerke, D.P. A Comparative Linear Interaction Energy and MM/PBSA Study on SIRT1–Ligand Binding Free Energy Calculation. J. Chem. Inf. Model. 2019, 59, 4018–4033. [Google Scholar] [CrossRef]
- Bang, S.; Cho, S. Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA) Study of Mutagen X. Bull. Korean Chem. Soc. 2004, 25, 1525–1530. [Google Scholar] [CrossRef] [Green Version]
- Gadhe, C.G.; Madhavan, T.; Kothandan, G.; Cho, S.J. In Silico Quantitative Structure-Activity Relationship Studies on P-gp Modulators of Tetrahydroisoquinoline-Ethyl-Phenylamine Series. BMC Struct. Biol. 2011, 11, 5. [Google Scholar] [CrossRef] [Green Version]
- Zięba, A.; Laitinen, T.; Patel, J.; Poso, A.; Kaczor, A. Docking-Based 3D-QSAR Studies for 1,3,4-oxadiazol-2-one Derivatives as FAAH Inhibitors. Int. J. Mol. Sci. 2021, 22, 6108. [Google Scholar] [CrossRef]
- Gadhe, C.G.; Kothandan, G.; Cho, S.J. Large variation in electrostatic contours upon addition of steric parameters and the effect of charge calculation schemes in CoMFA on mutagenicity of MX analogues. Mol. Simul. 2012, 38, 861–871. [Google Scholar] [CrossRef]
- San Juan, A.A.; Cho, S.J. 3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors. J. Mol. Model. 2007, 13, 601–610. [Google Scholar] [CrossRef] [PubMed]
- Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Pires, D.E.V.; Blundell, T.L.; Ascher, D.B. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Med. Chem. 2015, 58, 4066–4072. [Google Scholar] [CrossRef]
Complexes | MM-PB(GB)SA Binding Energy Terms in kcal/mol | LIE (kcal/mol) | ||||||
---|---|---|---|---|---|---|---|---|
VDWAALS | EEL | EPB/GB | ESURF | ΔGgas | ΔGsolv | ΔTOTAL | ΔGbind | |
FLT3-M01 | −71.17 | −51.49 | 68.69 | −8.82 | −122.66 | 59.86 | −62.80 | −18.39 |
FLT3-M03 | −72.23 | −275.18 | 295.32 | −8.72 | −347.42 | 286.60 | −60.27 | −13.43 |
FLT3-M17 | −53.77 | −21.27 | 34.20 | −6.48 | −75.04 | 27.72 | −47.32 | −12.56 |
FLT3-M20 | −69.48 | −222.37 | 240.20 | −9.02 | −291.85 | 231.17 | −60.68 | −19.35 |
FLT3-M24 | −62.38 | −28.98 | 39.64 | −7.83 | −91.36 | 31.80 | −59.56 | −9.75 |
FLT3-M34 | −56.90 | −248.23 | 262.59 | −6.76 | −305.14 | 255.82 | −49.31 | −8.14 |
FLT3(D835Y)-M01 | −70.94 | −51.33 | 67.31 | −8.58 | −122.28 | 58.72 | −63.55 | −18.39 |
FLT3(F691L)-M01 | −69.99 | −53.10 | 69.92 | −8.86 | −123.09 | 61.05 | −62.03 | −17.95 |
FLT3(D835Y,F691L)-M01 | −70.43 | −50.96 | 67.16 | −8.56 | −121.39 | 58.60 | −62.79 | −17.95 |
Residues | Compounds | ||||||||
---|---|---|---|---|---|---|---|---|---|
M01 | M03 | M17 | M20 | M24 | M34 | M01 (F691L) | M01 (D835Y) | M01 (F691L, D835Y) | |
K614 | NA | NA | NA | NA | NA | NA | −1.92 | −0.66 | −0.93 |
L616 | −2.53 | −1.90 | −2.20 | −2.20 | −1.13 | −2.44 | −2.35 | −2.38 | −2.63 |
V624 | NA | −1.61 | −0.60 | −1.50 | −1.54 | NA | −1.68 | −1.60 | −1.48 |
A642 | −1.25 | −1.26 | NA | −1.04 | −1.00 | −1.05 | −1.24 | −1.30 | −1.38 |
K644 | −2.15 | −2.26 | 0.36 | −1.43 | −0.75 | −0.38 | −1.84 | −1.24 | −2.24 |
M665 | −1.48 | −1.63 | −0.96 | −0.99 | −1.39 | −0.46 | −1.46 | −1.40 | −1.42 |
I674 | −1.03 | −1.26 | NA | −0.98 | NA | NA | −0.92 | −1.29 | −0.91 |
V675 | −1.81 | NA | NA | −0.98 | −1.64 | −0.93 | −1.69 | −1.67 | −1.62 |
F691 | −2.44 | −2.80 | −3.63 | −2.54 | −2.76 | −2.15 | −1.40 * | −2.63 | −1.09 * |
Y693 | −1.99 | −2.04 | −0.68 | −1.73 | −2.04 | −1.38 | −1.77 | −1.98 | −1.98 |
C694 | −2.82 | −2.24 | −0.13 | −0.74 | −2.41 | −0.77 | −2.77 | −2.72 | −2.81 |
G697 | −1.39 | −0.77 | −1.47 | −1.29 | −0.39 | −1.72 | −1.33 | −1.41 | −1.40 |
L818 | −1.76 | −1.67 | −1.89 | −1.67 | −1.56 | −1.70 | −1.78 | −1.68 | −1.64 |
C828 | −2.81 | −2.86 | NA | NA | −4.17 | −0.96 | −2.79 | −3.27 | −2.42 |
D829 | −1.22 | −1.41 | −2.21 | −1.12 | −0.94 | −2.08 | −1.19 | −1.29 | −1.73 |
F830 | −0.78 | −2.35 | −1.63 | −1.71 | −1.17 | −1.61 | NA | NA | NA |
Statistical Parameters | 3D-QSAR (All Compounds) | 3D-QSAR (Training Set Compounds) | Threshold Values | |||||
---|---|---|---|---|---|---|---|---|
CoMFA | CoMSIA (SEHA) | CoMFA | CoMSIA (SHD) | CoMSIA (SEHA) | CoMSIA (SEHD) | CoMSIA (SEHAD) | ||
q2 | 0.735 | 0.725 | 0.802 | 0.730 | 0.726 | 0.725 | 0.721 | >0.5 |
ONC | 6 | 5 | 6 | 5 | 5 | 5 | 5 | |
SEP | 0.502 | 0.503 | 0.452 | 0.517 | 0.521 | 0.522 | 0.525 | |
r2 | 0.956 | 0.912 | 0.983 | 0.960 | 0.962 | 0.965 | 0.956 | >0.6 |
SEE | 0.204 | 0.284 | 0.134 | 0.199 | 0.194 | 0.186 | 0.209 | <<1 |
F-value | 119.97 | 70.84 | 216.62 | 114.54 | 121.34 | 131.90 | 104.16 | >100 |
χ2 | 0.052 | 0.078 | 0.012 | 0.028 | 0.027 | 0.023 | 0.028 | <0.5 |
RMSE | 0.219 | 0.265 | 0.119 | 0.181 | 0.176 | 0.169 | 0.189 | <0.3 |
MAE | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ≈0 |
RSS | 1.873 | 2.744 | 0.412 | 0.953 | 0.904 | 0.834 | 1.046 | |
k | NA | NA | 1.033 | 1.022 | 1.032 | 1.033 | 1.037 | 0.85 ≤ k ≤ 1.15 |
k′ | NA | NA | 0.962 | 0.969 | 0.962 | 0.961 | 0.958 | 0.85 ≤ k′ ≤ 1.15 |
|r02− r′02| | NA | NA | 0.109 | 0.307 | 0.250 | 0.224 | 0.192 | <0.3 |
(r2 − r02)/r2 | NA | NA | 0.041 | 0.002 | 0.012 | 0.006 | 0.117 | <0.1 |
rm2 | NA | NA | 0.724 | 0.603 | 0.635 | 0.649 | 0.664 | >0.5 |
NA | NA | 0.694 | 0.449 | 0.492 | 0.511 | 0.623 | >0.5 | |
Δrm2 | NA | NA | 0.059 | 0.307 | 0.286 | 0.274 | 0.083 | |
NA | NA | 0.698 | 0.604 | 0.656 | 0.668 | 0.660 | >0.6 | |
NA | NA | 0.821 | 0.746 | 0.778 | 0.787 | 0.787 | ||
S (%) | 52.9 | 20.2 | 54.4 | 28.9 | 18.5 | 20.5 | 16.2 | |
E (%) | 47.1 | 29.9 | 45.6 | NA | 28.8 | 29.9 | 24.5 | |
H% | NA | 37.0 | NA | 47.3 | 33.9 | 32.8 | 28.3 | |
A% | NA | 13.0 | NA | NA | 18.8 | NA | 16.0 | |
D% | NA | NA | NA | 23.8 | NA | 16.8 | 15.1 |
Components | CoMFA | CoMSIA (SEHD) | ||||
---|---|---|---|---|---|---|
Q2 | cSDEP | dq2/dr2yy′ | Q2 | cSDEP | dq2/dr2yy′ | |
1 | 0.191 | 0.828 | 0.175 | 0.230 | 0.807 | 0.306 |
2 | 0.358 | 0.750 | 0.731 | 0.429 | 0.707 | 0.996 |
3 | 0.477 | 0.689 | 0.855 | 0.491 | 0.662 | 1.052 |
4 | 0.489 | 0.696 | 1.480 | 0.550 | 0.652 | 1.221 |
5 | 0.479 | 0.711 | 1.821 | 0.518 | 0.770 | 0.982 |
6 | 0.502 | 0.713 | 1.198 | 0.410 | 0.709 | 1.513 |
7 | 0.518 | 0.718 | 1.663 | 0.400 | 0.796 | 2.285 |
Complexes | MM-PB(GB)SA Binding Energy Terms in kcal/mol | ||||||
---|---|---|---|---|---|---|---|
VDWAALS | EEL | EPB/GB | ESURF | ΔGgas | ΔGsolv | ΔTOTAL | |
FLT3-D01 | −71.01 | −45.14 | 66.81 | −8.84 | −116.16 | 57.96 | −58.19 |
FLT3-D02 | −70.82 | −32.90 | 49.71 | −9.17 | −103.73 | 40.53 | −63.19 |
FLT3-D03 | −71.38 | −55.60 | 71.34 | −9.04 | −126.98 | 62.30 | −64.68 |
FLT3-D04 | −72.37 | −54.24 | 71.68 | −9.30 | −126.62 | 62.38 | −64.24 |
FLT3-D05 | −76.94 | −63.43 | 79.81 | −9.90 | −140.38 | 69.90 | −70.47 |
FLT3-D07 | −73.59 | −48.56 | 60.95 | −9.45 | −122.15 | 51.49 | −70.66 |
FLT3-D08 | −72.79 | −33.30 | 50.01 | −8.72 | −106.10 | 41.29 | −64.81 |
FLT3-D09 | −74.03 | −54.80 | 78.07 | −9.34 | −128.84 | 68.73 | −60.10 |
FLT3-D10 | −69.67 | −49.27 | 71.01 | −9.41 | −118.94 | 61.59 | −57.35 |
FLT3-D11 | −80.40 | −37.05 | 71.92 | −10.24 | −117.45 | 61.68 | −55.77 |
FLT3-D12 | −76.69 | −27.84 | 46.29 | −9.39 | −104.53 | 36.90 | −67.63 |
FLT3-D14 | −80.42 | −28.40 | 56.25 | −10.07 | −108.82 | 46.17 | −62.65 |
FLT3-D15 | −78.07 | −57.04 | 70.96 | −9.45 | −135.11 | 61.50 | −73.61 |
FLT3-D17 | −66.50 | −64.74 | 81.42 | −8.66 | −131.24 | 72.75 | −58.49 |
FLT3-D21 | −72.32 | −17.78 | 46.93 | −9.08 | −90.11 | 37.84 | −52.27 |
FLT3-D22 | −73.23 | −25.85 | 45.39 | −9.44 | −79.08 | 35.94 | −63.14 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ghosh, S.; Keretsu, S.; Cho, S.J. Molecular Modeling Studies of N-phenylpyrimidine-4-amine Derivatives for Inhibiting FMS-like Tyrosine Kinase-3. Int. J. Mol. Sci. 2021, 22, 12511. https://doi.org/10.3390/ijms222212511
Ghosh S, Keretsu S, Cho SJ. Molecular Modeling Studies of N-phenylpyrimidine-4-amine Derivatives for Inhibiting FMS-like Tyrosine Kinase-3. International Journal of Molecular Sciences. 2021; 22(22):12511. https://doi.org/10.3390/ijms222212511
Chicago/Turabian StyleGhosh, Suparna, Seketoulie Keretsu, and Seung Joo Cho. 2021. "Molecular Modeling Studies of N-phenylpyrimidine-4-amine Derivatives for Inhibiting FMS-like Tyrosine Kinase-3" International Journal of Molecular Sciences 22, no. 22: 12511. https://doi.org/10.3390/ijms222212511